Patients with cancer have an increased risk of venous-and arterial thromboembolism
(VTE/ATE). Anti-cancer treatments including surgery, radiotherapy, and certain …

Thromboembolic complications, including venous thromboembolism (VTE) and arterial
thromboembolism (ATE), increase mortality and morbidity, and delay treatment in patients …

Patients with cancer have an increased risk of both arterial and venous thrombotic events
compared with the general population. Both the site and stage of cancer are known to …

Risk factors for cancer-associated thrombosis are commonly divided into three categories:
patient-, cancer-, and treatment-related factors. Currently, different types of drugs are used in …

Background Venous thromboembolism (VTE) is known to complicate several classes of anti-
cancer therapies including chemotherapy and anti-angiogenic agents. Immunotherapy is a …

Venous thromboembolism (VTE) is a clinical disease that includes deep vein thrombosis
and pulmonary embolism. Amongst its underlying risk factors, cancer is of great importance …

Cancer is an independent and major risk factor for venous thromboembolism (VTE), defined
by symptomatic or asymptomatic DVT, including catheter-related thrombosis (CRT), and/or …

Venous thromboembolic (VTE) complications are common in patients with cancer and
represent the second cause of death in this disease. The risk of VTE varies according to the …

It remains unclear if immune checkpoint inhibitor (ICI) therapy is associated with higher rate
of venous thromboembolism (VTE) compared with cytotoxic chemotherapy (chemo) in …

Background Cancer and cancer therapies have been associated with an increased
incidence of venous thromboembolic events (VTE). However, the incidence of VTE in …